More information:
Leo I. Gordon et al, Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659), Oncotarget (2023). DOI: 10.18632/oncotarget.28352
healthmedicinet
Daily News and Tips